Methods of treating chronic pain

1. A method of treatment of chronic bone cancer pain and/or symptoms of chronic bone cancer pain in an individual, the method comprising administering to the individual a therapeutically effective amount of an anti-CGRP antagonist antibody.

2. The method according to claim 1 , wherein the anti-CGRP antagonist antibody is peripherally administered.

3. The method according to claim 1 , wherein the anti-CGRP antagonist antibody is administered orally, sublingually, via inhalation, transdermally, subcutaneously, intravenously, intra-arterially, intra-articularly, peri-articularly, locally and/or intramuscularly.

4. The method according to claim 3 , wherein the anti-CGRP antagonist antibody is administered subcutaneously or intravenously.

5. The method according to claim 1 , wherein the anti-CGRP antagonist antibody acts peripherally on administration.

6. The method according to claim 1 , wherein the chronic bone cancer pain further comprises one or more of hyperalgesia, allodynia, central sensitisation, peripheral sensitisation, disinhibition and augmented facilitation.

7. The method according to claim 1 , wherein the chronic bone cancer pain is pain due to one or more of the following conditions: myeloma in bone marrow, sarcoma in connective or supportive tissue, cancer of bone tissue, cancer of blood-forming cells, cancer of bone marrow, multiple myeloma, leukaemia, primary or secondary bone cancer, tumours that metastasize to the bone, bone tumours infiltrating the nerve and hollow viscus, and bone tumours near neural structures.

8. The method according to claim 1 , wherein the anti-CGRP antagonist antibody: (a) binds to CGRP; (b) blocks CGRP from binding to its receptor; (c) blocks or decreases CGRP receptor activation; (d) inhibits blocks, suppresses or reduces CGRP biological activity; (e) increases clearance of CGRP; and/or (g) inhibits CGRP synthesis, production or release.

9. The method according to claim 1 , wherein the anti-CGRP antagonist antibody: (i) is a human antibody, (ii) is a humanized antibody, (iii) is a monoclonal antibody, (iv) binds CGRP with a Kd of 50 nM or less (as measured by surface plasmon resonance at 37° C.); and/or (v) has a half life in-vivo of at least 7 days.

10. The method according to claim 9 , wherein the anti-CGRP antagonist antibody specifically binds to amino acid residues 33-37 of SEQ ID NO:15.

11. The method according to claim 1 , wherein the anti-CGRP antagonist antibody specifically binds to the C-terminal region of CGRP.

12. The method according to claim 1 , wherein the anti-CGRP antibody comprises:

(a) CDR H1 as set forth in SEQ ID NO: 3 or 21;

(b) CDR H2 as set forth in SEQ ID NO: 4 or SEQ ID NO: 22;

(c) CDR H3 as set forth in SEQ ID NO: 5 or 23;

(d) CDR L1 as set forth in SEQ ID NO: 6 or SEQ ID NO: 24;

(e) CDR L2 as set forth in SEQ ID NO: 7 or SEQ ID NO: 25;

(f) CDR L3 as set forth in SEQ ID NO: 8 or 26;

wherein the antibody binds CGRP with a Kd of 50 nM or less as measured by surface plasmon resonance at 37° C.

13. The method according to claim 1 , wherein the anti-CGRP antibody comprises a VH domain that comprises the amino acid sequence to SEQ ID NO: 1 and a VL domain that comprises the amino acid sequence to SEQ ID NO: 2.

14. The method according to claim 1 , wherein the anti-CGRP antibody comprises a) a heavy chain produced by the expression vector with ATCC Accession No. PTA-6867; b) a light chain produced by the expression vector with ATCC Accession No. PTA-6866 or c) an anti-CGRP antibody produced by the expression vectors with ATCC Accession Nos. PTA-6867 and PTA-6866.